<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=176186"><dc:title>New insights into interstitial cystitis/bladder pain syndrome at single-cell resolution</dc:title><dc:creator>Kuret,	Tadeja	(Avtor)
	</dc:creator><dc:creator>Erdani-Kreft,	Mateja	(Avtor)
	</dc:creator><dc:subject>bladder pain syndrome</dc:subject><dc:subject>high throughput</dc:subject><dc:subject>immune cells</dc:subject><dc:subject>interstitial cells</dc:subject><dc:subject>interstitial cystitis</dc:subject><dc:subject>single-cell landscape</dc:subject><dc:subject>urothelial cells</dc:subject><dc:description>Objective: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic inflammatory bladder disorder with unknown aetiology and limited treatment options. Single-cell RNA-sequencing (scRNA-seq) has provided unprecedented insights into cellular heterogeneity in IC/BPS. This review summarizes recent scRNA-seq findings on bladder cell populations, emphasizing urothelial, interstitial and immune cells. 
Methods: A comprehensive analysis of published scRNA-seq studies was conducted to compare bladder cell subtypes in healthy and IC/BPS-affected bladders. Differences between IC/BPS patients and mouse models, as well as sex-specific cellular variations, were examined. 
Results: IC/BPS bladders exhibit significant urothelial alterations, including a reduction in UPK3A + umbrella cells and an expansion of progenitor-like cells with impaired regenerative capacity, linked to TLR3-NR2F6 signalling. Interstitial cells include three fibroblast subtypes (PDGFRA+, RGS5+ and pro-inflammatory IL6-producing fibroblasts), which contribute to fibrosis and inflammation. The immune landscape is characterized by a Th1-biased response, exhausted CD8 + T cells and reduced regulatory T cells, with HPV infection detected in most IC/BPS patients, suggesting a possible viral aetiology. Cell-to-cell interactions are compromised, with enhanced macrophage-endothelial signalling via CXCL8-ACKR1 and CXCL2/3-ACKR1 pathways, highlighting potential therapeutic targets. Notably, sex-based differences reveal stronger immune activation in females and increased urothelial proliferation in males, potentially explaining the higher IC/BPS prevalence in females. 
Conclusions: scRNA-seq has advanced our understanding of IC/BPS by identifying disease-associated cell types, signalling pathways and intercellular interactions. Future research should integrate multi-omics approaches and explore non-invasive urine-based scRNA-seq for improved diagnosis and therapy.</dc:description><dc:date>2025</dc:date><dc:date>2025-11-24 13:16:06</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>176186</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
